NEJM shared a post on LinkedIn:
“In patients with HER2-positive early breast cancer and residual disease after neoadjuvant therapy, trastuzumab deruxtecan improved invasive disease–free survival but carried a risk of interstitial lung disease. Full phase 3 DESTINY-Breast05 trial results and Research Summary”
Title: Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
Authors: Sibylle Loibl, Yeon Hee Park, Zhiming Shao, Chiun-Sheng Huang, Carlos Barrios, Jame Abraham, Aleix Prat, Naoki Niikura, Seock-Ah Im, Wei Li, Huiping Li, Yongsheng Wang, Herui Yao, Sung-Bae Kim, Cui-zhi Geng, Wuilbert Rodriguez Pantigoso, Francisco Javier Ramírez Godinez, Chuangui Song, Yuan Ching Chang, Augusto Antoniazzi, Shin-Cheh Chen, Zhigao Li, Zbigniew Nowecki, Joline Lim, Elton Mathias, Yuta Sato, Wenjing Lu, Hanan Abdel-Monem, Michael Untch and Charles E. Geyer.
Other articles featuring NEJM on OncoDaily.